MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1183/13993003.00217-2017

Медицинская библиотека · The European respiratory journal · 2017

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald Jason, Chaumais Marie-Camille, Savale Laurent, Jaïs Xavier, Seferian Andrei, Canuet Matthieu, Bouvaist Hélène, Magro Pascal, Bergeron Anne, Guignabert Christophe, Sitbon Olivier, Simonneau Gérald, Humbert Marc, Montani David

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical and haemodynamic variables were compared from baseline to last follow-up (median (range) 24 (1-81) months).Median age was 52 years and 15 patients were female (71%). 19 patients received dasatinib for chronic myelogenous leukaemia for a median (range) duration of 42 (8-74) months before PAH diagnosis. No bone morphogenic protein receptor-2 (BMPR2) mutations were found in the 10 patients tested. Dasatinib was uniformly discontinued and 11 patients received PAH medications. Four patients died during follow-up. New York Heart Association functional class improved from 76% in class III/IV to 90% in class I/II (p<0.01). Median (range) 6-min walk distance improved from 306 (0-660) to 430 (165-635) m (p<0.01). Median (range) mean pulmonary arterial pressure improved from 45 (30-70) to 26 (17-50) mmHg (p<0.01) and pulmonary vascular resistance from 6.1 (3.2-27.3) to 2.6 (1.2-5.9) Wood units (p<0.01). Patients treated with PAH medications had worse baseline haemodynamics but similar long-term outcomes to untreated patients. PAH persisted in 37% of patients.Dasatinib-induced PAH frequently improves after discontinuation but persisted in over one-third of patients, therefore systematic follow-up is essential.

Для цитирования: Weatherald Jason, Chaumais Marie-Camille, Savale Laurent, Jaïs Xavier, Seferian Andrei, Canuet Matthieu, Bouvaist Hélène, Magro Pascal, Bergeron Anne, Guignabert Christophe, Sitbon Olivier, Simonneau Gérald, Humbert Marc, Montani David. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.. The European respiratory journal. 2017. DOI: 10.1183/13993003.00217-2017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.